___

• 1. Podschun, R., Ullmann, U. (1998). Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clinical Microbiology Reviews, 11(4), 589- 603. [CrossRef]
• 2. Moxon, C. A., Paulus, S. (2016). Beta-lactamases in Enterobacteriaceae infections in children. Journal of Infection, 72 Suppl, S41-49. [CrossRef]
• 3. Bitsori, M., Galanakis, E. (2019). Treatment of urinary tract infections caused by ESBL- producing Escherichia coli or Klebsiella pneumoniae. The Pediatric Infectious Disease Journal, 38(12), e332-e335. [CrossRef]
• 4. Peleg, A. Y., Hooper, D. C. (2010). Hospital-acquired infections due to gram-negative bacteria. New England Journal of Medicine, 362(19), 1804-1813. [CrossRef]
• 5. Golkar, Z., Bagasra, O., Pace, D. G. (2014). Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. The Journal of Infection in Developing Countries, 8(2), 129-136. [CrossRef]
• 6. Chanishvili, N. (2012). A literature review of the practical application of bacteriophage research. New York: Nova Biomedical Books.
• 7. Bruttin, A., Brüssow, H. (2005). Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrobial Agents and Chemotherapy, 49(7), 2874-2878. [CrossRef]
• 8. Domingo-Calap, P., Delgado-Martinez, J. (2018). Bacteriophages: protagonists of a post- antibiotic era. Antibiotics (Basel), 7(3), 1-16. [CrossRef]
• 9. Kazi, M., Annapure, U. S. (2016). Bacteriophage biocontrol of foodborne pathogens. Journal of Food Science and Technology, 53(3), 1355-1362. [CrossRef]
• 10. Guttman, B., Raya, R., Kutter, E. (2005). Basic phage biology. Bacteriophages: Biology and applications, 4.
• 11. Harper, D. R., Parracho, H. M. R. T., Walker, J., Sharp, R., Hughes, G., Werthén, M., Morales, S. (2014). Bacteriophages and biofilms. Antibiotics, 3(3), 270-284. [CrossRef]
• 12. Kochetkova, V. A., Mamontov, A. S., Moskovtseva, R. L., Erastova, E. I., Trofimov, E. I., Popov, M. I., Dzhubalieva, S. K. (1989). Phagotherapy of postoperative suppurative-inflammatory complications in patients with neoplasms. Sovetskaia Meditsina, (6), 23-26.
• 13. Domingo-Calap, P., Beamud, B., Mora-Quilis, L., González-Candelas, F., Sanjuán, R. (2020). Isolation and characterization of two Klebsiella pneumoniae phages encoding divergent depolymerases. International Journal of Molecular Sciences, 21(9), 3160. [CrossRef]
• 14. Karamoddini, M. K., Fazli-Bazzaz, B. S., Emamipour, F., Ghannad, M. S., Jahanshahi, A. R., Saed, N., & Sahebkar, A. (2011a). Antibacterial efficacy of lytic bacteriophages against antibiotic-resistant Klebsiella species. The Scientific World Journal, 11, 370161. [CrossRef]
• 15. Kumari, S., Harjai, K., Chhibber, S. (2011). Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. Journal of Medical Microbiology, 60(Pt 2), 205-210. [CrossRef]
• 16. Wintachai, P., Naknaen, A., Thammaphet, J., Pomwised, R., Phaonakrop, N., Roytrakul, S., Smith, D. R. (2020). Characterization of extended-spectrum-β-lactamase producing Klebsiella pneumoniae phage KP1801 and evaluation of therapeutic efficacy in vitro and in vivo. Scientific Reports, 10(1), 11803. [CrossRef]
• 17. Adams, M. H. (1959). Bacteriophages: Interscience publishers.
• 18. Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Vaneechoutte, M. (2009). Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One, 4(3), e4944-e4944. [CrossRef]
• 19. Oliveira, H., Pinto, G., Oliveira, A., Oliveira, C., Faustino, M. A., Briers, Y., Azeredo, J. (2016). Characterization and genome sequencing of a Citrobacter freundii phage CfP1 harboring a lysin active against multidrug-resistant isolates. Applied Microbiology and Biotechnology, 100(24), 10543-10553. [CrossRef]
• 20. Sambrook, J., Fritsch, E. F., Maniatis, T. (1989). Molecular cloning: a laboratory manual: Cold spring harbor laboratory press.
• 21. Sasikala, D., Srinivasan, P. (2016). Characterization of potential lytic bacteriophage against Vibrio alginolyticus and its therapeutic implications on biofilm dispersal. Microbial Pathogenesis, 101, 24-35. [CrossRef]
• 22. Knezevic, P., Kostanjsek, R., Obreht, D., Petrovic, O. (2009). Isolation of Pseudomonas aeruginosa specific phages with broad activity spectra. Current Microbiology, 59(2), 173. [CrossRef]
• 23. Herridge, W. P., Shibu, P., O'Shea, J., Brook, T. C., Hoyles, L. (2020). Bacteriophages of Klebsiella spp., their diversity and potential therapeutic uses. Journal of Medical Microbiology, 69(2), 176-194. [CrossRef]
• 24. Harper, D. R. (2018). Criteria for selecting suitable infectious diseases for phage therapy. Viruses, 10(4), 177. [CrossRef]
• 25. Townsend, E. M., Kelly, L., Gannon, L., Muscatt, G., Dunstan, R., Michniewski, S., Jameson, E. (2021). Isolation and characterization of Klebsiella phages for phage therapy. Phage (New Rochelle), 2(1), 26-42. [CrossRef]
• 26. Karumidze, N., Kusradze, I., Rigvava, S., Goderdzishvili, M., Rajakumar, K., Alavidze, Z. (2013). Isolation and characterisation of lytic bacteriophages of Klebsiella pneumoniae and Klebsiella oxytoca. Current Microbiology, 66(3), 251-258. [CrossRef]
• 27. Karamoddini, M. K., Fazli-Bazzaz, B. S., Emamipour, F., Ghannad, M. S., Jahanshahi, A. R., Saed, N., Sahebkar, A. (2011b). Antibacterial efficacy of lytic bacteriophages against antibiotic- resistant Klebsiella species. The Scientific World Journal, 11, 1332-1340. [CrossRef]
• 28. Drulis-Kawa, Z., Mackiewicz, P., Kęsik-Szeloch, A., Maciaszczyk-Dziubinska, E., Weber- Dąbrowska, B., Dorotkiewicz-Jach, A., Kropinski, A. M. (2011). Isolation and characterisation of KP34—a novel φKMV-like bacteriophage for Klebsiella pneumoniae. Applied Microbiology and Biotechnology, 90(4), 1333-1345. [CrossRef]